February 22nd 2022
Discussion on the role of transplantation in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
February 15th 2022
The significance of having novel therapies and molecular tests available to help guide treatment decisions for patients with B-cell acute lymphoblastic leukemia, and recommendations on how to increase the uptake of MRD testing into routine clinical practice.
When to test for measurable residual disease in B-cell acute lymphoblastic leukemia, and what to keep in mind when selecting a testing method to help assess MRD.
February 8th 2022
Emerging therapies in the clinical pipeline for relapsed/refractory B-cell acute lymphoblastic leukemia, as presented at ASH 2021.
An overview of adverse events commonly associated with CAR T-cell therapies in relapsed/refractory B-cell acute lymphoblastic leukemia.
February 1st 2022
Recommendations for sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.
Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
January 25th 2022
The treatment approaches available for patients with B-cell acute lymphoblastic leukemia, and reactions to the availability of novel CAR T therapies for relapsed/refractory disease.
Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.
January 29th 2021
Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.
January 19th 2021
Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.
December 17th 2020
Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.
August 23rd 2018
Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.
August 2nd 2018
Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia.
October 29th 2016
Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent treatment advances and emerging subsets in acute lymphoblastic leukemia (ALL).
May 31st 2016
Elias Jabbour, MD, associate professor, department of leukemia, division of cancer medicine, the University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) for acute lymphocytic leukemia (ALL).
March 15th 2011
Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.
Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.